Aché Laboratórios Farmacêuticos SA has synthesized compounds acting as β2-adrenoceptor (ADRB2) agonists and muscarinic M3 receptor antagonists reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and rhinitis.
Chiesi Farmaceutici SpA presented data for novel lung-targeted muscarinic M3 receptor antagonists/β2-adrenoceptor agonists (MABAs) as candidates for the treatment of chronic obstructive pulmonary disease (COPD).
